Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF). 1993

H Tamai, and T Mukuta, and S Matsubayashi, and S Fukata, and G Komaki, and K Kuma, and L F Kumagai, and S Nagataki
Department of Psychosomatic Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

Agranulocytosis, although extremely infrequent, is a serious complication of antithyroidal drug therapy in patients with hyperthyroidism. Presently, there is no specific therapy for this life-threatening complication, and recovery time is highly variable. Recently, recombinant human granulocyte colony-stimulating factor (rhG-CSF) was reported to be effective in shortening the recovery time of the neutropenia in patients undergoing chemotherapy. The present study was undertaken to determine the efficacy of rhG-CSF administration in patients with methimazole-induced (MMI) agranulocytosis. Thirty-four patients (7 males and 27 females, ages 16-68 yr) with MMI agranulocytosis were divided into 3 groups: group A (n = 11) was treated with antibiotics only; group B (n = 11) received antibiotics and dexamethasone, 8 mg/day; and group C (n = 12) was treated with antibiotics and im injections of rhG-CSF, 75 micrograms/day. Patients in groups A and B were studied retrospectively. When rhG-CSF became available, patients in group C were studied prospectively. Bone marrow sternal punctures were performed in all group C patients who were then divided into 2 subgroups according to the granulocyte to erythrocyte count ratio (G:E). Group C1 (n = 6) had a G:E ratio of less than 0.5, and group C2 (n = 6) had a ratio of more than or equal to 0.5. Recovery time in all groups was defined as the number of days required for the peripheral granulocyte count to be greater than 1.0 x 10(9)/L. There was no significant difference in recovery time between groups A and B: 10.1 +/- 2.2 and 12.3 +/- 1.9 days (mean +/- SE), respectively. P was not significant; the administration of dexamethasone proved to be ineffective in shortening the time for recovery from peripheral granulocytes. On the other hand, recovery time was significantly shorter in group C (6.8 +/- 1.2 days mean +/- SE) compared with groups A and B (P < 0.05). Group C2 recovered in 2.2 +/- 0.6 days whereas group C1 took much longer, 9.8 +/- 1.3 days (P < 0.001). There was a direct correlation between the G:E ratio and the peripheral leucocyte count, r = 0.806, P < 0.01. Furthermore, rhG-CSF significantly shortened recovery time when the peripheral granulocyte count was greater than 0.1 x 10(9)/L (group C2) compared with patients whose counts were less than 0.1 x 10(9)/L (group C1), 2.2 +/- 0.4 vs. 8.6 +/- 1.3 days, respectively (P < 0.001). These data indicate that administration of steroids is ineffective in shortening the duration of recovery in patients with MMI agranulocytosis.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008713 Methimazole A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme. Methymazol,Thiamazole,1-Methyl-2-mercaptoimidazole,Favistan,Mercasolyl,Mercazol,Mercazole,Mercazolyl,Merkazolil,Methizol,Methylmercaptoimidazole,Metisol,Metizol,Strumazol,Tapazole,Thiamazol Henning,Thiamazol Hexal,Thimazol,Thyrozol,Tiamazol,Tirodril,1 Methyl 2 mercaptoimidazole,Henning, Thiamazol,Hexal, Thiamazol
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006098 Granulocytes Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS. Granulocyte
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000380 Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia,Agranulocytoses,Granulocytopenias
D016179 Granulocyte Colony-Stimulating Factor A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. Colony-Stimulating Factor, Granulocyte,G-CSF,Myeloid Growth Factor,Colony Stimulating Factor, Granulocyte,Factor, Granulocyte Colony-Stimulating,Factor, Myeloid Growth,Granulocyte Colony Stimulating Factor,Growth Factor, Myeloid

Related Publications

H Tamai, and T Mukuta, and S Matsubayashi, and S Fukata, and G Komaki, and K Kuma, and L F Kumagai, and S Nagataki
November 1995, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed,
H Tamai, and T Mukuta, and S Matsubayashi, and S Fukata, and G Komaki, and K Kuma, and L F Kumagai, and S Nagataki
November 1993, Journal of internal medicine,
H Tamai, and T Mukuta, and S Matsubayashi, and S Fukata, and G Komaki, and K Kuma, and L F Kumagai, and S Nagataki
January 1994, Thyroid : official journal of the American Thyroid Association,
H Tamai, and T Mukuta, and S Matsubayashi, and S Fukata, and G Komaki, and K Kuma, and L F Kumagai, and S Nagataki
January 1997, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
H Tamai, and T Mukuta, and S Matsubayashi, and S Fukata, and G Komaki, and K Kuma, and L F Kumagai, and S Nagataki
June 1995, Recenti progressi in medicina,
H Tamai, and T Mukuta, and S Matsubayashi, and S Fukata, and G Komaki, and K Kuma, and L F Kumagai, and S Nagataki
October 1989, Annals of internal medicine,
H Tamai, and T Mukuta, and S Matsubayashi, and S Fukata, and G Komaki, and K Kuma, and L F Kumagai, and S Nagataki
November 1994, Orvosi hetilap,
H Tamai, and T Mukuta, and S Matsubayashi, and S Fukata, and G Komaki, and K Kuma, and L F Kumagai, and S Nagataki
May 1992, American journal of hematology,
H Tamai, and T Mukuta, and S Matsubayashi, and S Fukata, and G Komaki, and K Kuma, and L F Kumagai, and S Nagataki
July 1992, Annals of hematology,
H Tamai, and T Mukuta, and S Matsubayashi, and S Fukata, and G Komaki, and K Kuma, and L F Kumagai, and S Nagataki
May 1993, Annals of hematology,
Copied contents to your clipboard!